



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti-PCSK9 [PA4] Standard Size Ab03945-3.3

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This is a reformatted mouse IgG2b Fc Silent™ antibody, based on the original mouse IgG1 format, created for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Mouse IgG2b, Fc Silent™, Kappa

Clone Number: PA4

Alternative Name(s) of Target: NARC1; NARC-1; PC9; Proprotein convertase subtilisin/kexin type; Neural apoptosis-regulated convertase 1; Proprotein convertase 9; Subtilisin/kexin-like protease PC9; PA4Fab

UniProt Accession Number of Target Protein: Q8NBP7

Published Application(s): inhibit, therapeutic, WB, Block, ELISA

Published Species Reactivity: Human

Immunogen: The original antibody was isolated from a natural human Fab phage display library by panning against recombinant human PCSK9. Later one the Fab antibody was converted to IgG1 format.

Specificity: This antibody binds human PCSK9. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease enzyme encoded by the PCSK9 gene in humans and it plays a role in regulation of circulating cholesterol. It is associated with autosomal dominant hypercholesterolemia, a state of elevated levels of LDL (low-density lipoprotein) cholesterol. Autosomal dominant hypercholesterolemia can result in severe implications such as stroke and coronary heart disease.

Application Notes: The human IgG1 format of this antibody was reported to bind human PCSK9 with a binding affinity $K_d = 1.05$ nM. The binding characterization of this antibody to human PCSK9 was done using ELISA and western blot. In an in vitro competition binding ELISA, IgG1-PA4 blocked PCSK9 from binding to LDLR, with an IC_{50} of approximately 7 nM. In vitro, it also attenuated PCSK9-mediated degradation of LDLR on the HepG2 cell surface in a dose dependent manner. In C57BL/6 mice, administration of IgG1-PA4 at 30 mg/kg increased hepatic LDLR protein levels by as much as 3 fold when compared with control. This antibody has potential for being used as a therapeutic for the treatment of hypercholesterolemia by inhibiting PCSK9-mediated degradation of cell surface LDLRs (PMID: 26056005).

Antibody First Published in: Cao et al. Selection and characterization of human PCSK9 antibody from phage displayed antibody library. Biochem Biophys Res Commun. 2015 Aug 7;463(4):712-8. [PMID:26056005](https://pubmed.ncbi.nlm.nih.gov/26056005/)

Note on publication: This paper describes the isolation of a Fab antibody that binds human PCSK9. The IgG1 format was generated and characterized.

Product Form

Size: 100 µg Purified antibody.

Purification: Protein A affinity purified

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.